AFP and metastatic neoplasm: The median overall survival was not significantly different based on portal vein thrombus vs. no portal vein thrombus (p = 0.87), metastatic disease vs. no metastatic disease (p = 0.13), prior locoregional therapy vs. no prior locoregional therapy (p = 0.47), age >65 vs. <65 (p = 0.73), Karnofsky Performance Status >80 vs. ≤80 (p = 0.18), bilobar vs. unilobar treatment (p = 0.87), or pre-RE AFP >400 vs. <400 ng/mL (p = 0.49).